MI-HARMAN
14.9.2022 15:27:35 CEST | Business Wire | Press release
HARMAN International, a wholly-owned subsidiary of Samsung Electronics Co., Ltd. focused on connected technologies and solutions for automotive, consumer and enterprise markets, today announced the introduction of Ready Care — the latest solution in its expanding portfolio of products designed and built to deliver consumer-focused experiences at an automotive grade. Ready Care is a set of solutions — Cognitive Distraction, Stress-Free Routing, and Personalized Comfort — that can work together or independently to improve safety and reduce driver stress.
Ready Care delivers heightened levels of safety and wellbeing through the integration of several key technologies. In addition to employing cameras that can detect driver drowsiness, Ready Care measures real-time driver cognitive load to identify when potential distractions arise, and then offers tailored intervention strategies to maximize safety. The experience is powered by newly developed machine learning algorithms, which gather and process data from in-vehicle cameras and sensors to monitor a driver’s state. Ready Care can then generate customized in-vehicle cabin prompts to trigger a range of behavioral responses — increasing awareness, alleviating stress, or stimulating relief.
“Safety remains a top concern for consumers when considering a new vehicle purchase, and now, with Ready Care, OEMs can improve vehicle safety in a significant new way,” said Armin Prommersberger, Senior Vice President, Automotive Product Management at HARMAN International. “Ready Care is essentially a co-pilot, spotting when distractions could turn into dangerous situations and intervening to avoid them. For the first time, the vehicle can, in a sense, know what the driver is thinking; this is a game changer. We are incredibly proud of and excited by the impact Ready Care will have for drivers, passengers, and everyone on the road.”
Key features of Ready Care include:
- Eyes and Mind on Road: Ready Care measures both driver eye activity and state of mind. An infra-red global shutter camera with active illumination surveys the driver’s face in low and high light environments to provide real-time data into facial expressions, eye gaze, eyelid openings, and more. The HARMAN Cognitive Distraction feature — a real-time driver visual and cognitive load measurement tool — deciphers when the driver is mentally distracted and can initiate multiple and simultaneous in-cabin vehicle intervention responses. It measures real-time driver cognitive load and separates driving tasks from other mental activities as well as visual and manual distractions to enable tailored intervention strategies that maximize safety.
- Stress-free Routing: Compatible with multiple navigation engines, Ready Care provides an alternate route selection to lower elevated driver stress levels while on the road. Through detecting real-time stress factors like traffic jams or weather and adapting accordingly, this solution helps mitigate the driver’s state of stress or anxiety.
- Personalized Experiences: As all journeys and drivers are unique, Ready Care leverages advanced machine learning technology to provide personalized intervention strategies tailored to the individual and their driving experience. Ready Care delivers closed-loop interventions via an SDK, allowing OEMs and third parties to integrate any vehicle feature or function — such as HVAC control, media content and volume, or seat sensors — into the Ready Care solution. An example could be the advanced technologies offered by Gentherm, the global market leader of innovative thermal management and pneumatic comfort technologies for the automotive industry.
Ready Care equips OEMs with advanced but meaningful technology to improve driver safety and wellbeing. Automotive manufacturers have the opportunity to incorporate the full set of Ready Care solutions into vehicles or choose specific features to create a more customized solution right for their customers and fleets.
For decades, HARMAN has been uniquely positioned at the intersection of automotive and consumer technology innovation, resulting in meaningful, industry-leading solutions. Through its key consumer and technology brands, deep industry expertise, and robust technology stack, HARMAN is equipped to deliver on the promise of consumer experiences through automotive-grade solutions today.
For more information on HARMAN’s Ready Care solution, visit car.harman.com/experiences/ready-care.
About HARMAN
HARMAN (harman.com) designs and engineers connected products and solutions for automakers, consumers, and enterprises worldwide, including connected car systems, audio and visual products, enterprise automation solutions; and services supporting the Internet of Things. With leading brands including AKG®, Harman Kardon®, Infinity®, JBL®, Lexicon®, Mark Levinson® and Revel®, HARMAN is admired by audiophiles, musicians and the entertainment venues where they perform around the world. More than 50 million automobiles on the road today are equipped with HARMAN audio and connected car systems. Our software services power billions of mobile devices and systems that are connected, integrated and secure across all platforms, from work and home to car and mobile. HARMAN has a workforce of approximately 30,000 people across the Americas, Europe, and Asia. In 2017, HARMAN became a wholly-owned subsidiary of Samsung Electronics Co., Ltd.
© 2022 HARMAN International Industries, Incorporated. All rights reserved. Harman Kardon, Infinity, JBL, Lexicon and Mark Levinson are trademarks of HARMAN International Industries, Incorporated, registered in the United States and/or other countries. AKG is a trademark of AKG Acoustics GmbH, registered in the United States and/or other countries. Features, specifications, and appearance are subject to change without notice.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220914005609/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
